Literature DB >> 16528611

An analysis of unclassified missense substitutions in human BRCA1.

Sean V Tavtigian1, Paul B Samollow, Deepika de Silva, Alun Thomas.   

Abstract

Classification of rare sequence variants observed during mutation screening of susceptibility genes in high-risk individuals presents an interesting and medically important challenge. A recently described method for analysis of unclassified variants in BRCA1 and BRCA2 provides an extensible framework within which several different types of analytic data can be integrated. Among the methods already integrated in this framework are a measure of sequence conservation at specific positions in BRCA1 and BRCA2, and a measure of the difference between wild-type and missense amino acid residues, the Grantham Matrix Score. Recently, we extended the idea of Grantham Matrix Scores to multiple sequence alignments by introducing two new measures, the Grantham variation and Grantham Deviation. We also created a measure of risk associated with sets of BRCA1 missense substitutions, the BRCA1-with-BRCA2 Ascertainment Ratio. Here, we complement these measures with a more powerful measure of risk associated with sets of missense substitutions, the Missense Enrichment Ratio. By combining these four measures, we demonstrate two points: (1) pooled evidence is completely in accord with a hypothesis that missense substitutions that fall at variable positions in the alignment of vertebrate BRCA1s and are within the range of variation observed at those positions are neutral, and (2) many of the missense substitutions falling at invariant positions in the alignment must be deleterious and the longer the period over which the position has been invariant, the stronger the evidence that this is so.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16528611     DOI: 10.1007/s10689-005-2578-0

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  17 in total

1.  Structure of a BRCA1-BARD1 heterodimeric RING-RING complex.

Authors:  P S Brzovic; P Rajagopal; D W Hoyt; M C King; R E Klevit
Journal:  Nat Struct Biol       Date:  2001-10

2.  Structure of the BRCT repeats of BRCA1 bound to a BACH1 phosphopeptide: implications for signaling.

Authors:  Eric N Shiozaki; Lichuan Gu; Nieng Yan; Yigong Shi
Journal:  Mol Cell       Date:  2004-05-07       Impact factor: 17.970

3.  Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation.

Authors:  V Abkevich; A Zharkikh; A M Deffenbaugh; D Frank; Y Chen; D Shattuck; M H Skolnick; A Gutin; S V Tavtigian
Journal:  J Med Genet       Date:  2004-07       Impact factor: 6.318

4.  Deleterious mutations and neutral substitutions.

Authors:  T H Jukes; J L King
Journal:  Nature       Date:  1971-05-14       Impact factor: 49.962

5.  An improved method for determining codon variability in a gene and its application to the rate of fixation of mutations in evolution.

Authors:  W M Fitch; E Markowitz
Journal:  Biochem Genet       Date:  1970-10       Impact factor: 1.890

6.  Molecules as documents of evolutionary history.

Authors:  E Zuckerkandl; L Pauling
Journal:  J Theor Biol       Date:  1965-03       Impact factor: 2.691

Review 7.  Cancer susceptibility and the functions of BRCA1 and BRCA2.

Authors:  Ashok R Venkitaraman
Journal:  Cell       Date:  2002-01-25       Impact factor: 41.582

8.  Human non-synonymous SNPs: server and survey.

Authors:  Vasily Ramensky; Peer Bork; Shamil Sunyaev
Journal:  Nucleic Acids Res       Date:  2002-09-01       Impact factor: 16.971

9.  Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk.

Authors:  T S Frank; S A Manley; O I Olopade; S Cummings; J E Garber; B Bernhardt; K Antman; D Russo; M E Wood; L Mullineau; C Isaacs; B Peshkin; S Buys; V Venne; P T Rowley; S Loader; K Offit; M Robson; H Hampel; D Brener; E P Winer; S Clark; B Weber; L C Strong; A Thomas
Journal:  J Clin Oncol       Date:  1998-07       Impact factor: 44.544

10.  The amino-acid mutational spectrum of human genetic disease.

Authors:  Dennis Vitkup; Chris Sander; George M Church
Journal:  Genome Biol       Date:  2003-10-30       Impact factor: 13.583

View more
  11 in total

1.  Functional assays for classification of BRCA2 variants of uncertain significance.

Authors:  Daniel J Farrugia; Mukesh K Agarwal; Vernon S Pankratz; Amie M Deffenbaugh; Dmitry Pruss; Cynthia Frye; Linda Wadum; Kiley Johnson; Jennifer Mentlick; Sean V Tavtigian; David E Goldgar; Fergus J Couch
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

Review 2.  Growing recognition of the role for rare missense substitutions in breast cancer susceptibility.

Authors:  Sean V Tavtigian; Georgia Chenevix-Trench
Journal:  Biomark Med       Date:  2014       Impact factor: 2.851

3.  Multimodal assessment of protein functional deficiency supports pathogenicity of BRCA1 p.V1688del.

Authors:  Arcangela De Nicolo; Emilio Parisini; Quan Zhong; Maurizia Dalla Palma; Kathryn A Stoeckert; Susan M Domchek; Katherine L Nathanson; Maria A Caligo; Marc Vidal; Michael E Cusick; Judy E Garber
Journal:  Cancer Res       Date:  2009-08-25       Impact factor: 12.701

4.  A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes.

Authors:  Douglas F Easton; Amie M Deffenbaugh; Dmitry Pruss; Cynthia Frye; Richard J Wenstrup; Kristina Allen-Brady; Sean V Tavtigian; Alvaro N A Monteiro; Edwin S Iversen; Fergus J Couch; David E Goldgar
Journal:  Am J Hum Genet       Date:  2007-09-06       Impact factor: 11.025

5.  Functional impact of missense variants in BRCA1 predicted by supervised learning.

Authors:  Rachel Karchin; Alvaro N A Monteiro; Sean V Tavtigian; Marcelo A Carvalho; Andrej Sali
Journal:  PLoS Comput Biol       Date:  2006-12-28       Impact factor: 4.475

6.  Evaluation of BRCA1 and BRCA2 mutations and risk-prediction models in a typical Asian country (Malaysia) with a relatively low incidence of breast cancer.

Authors:  E Thirthagiri; S Y Lee; P Kang; D S Lee; G T Toh; S Selamat; S-Y Yoon; N A Mohd Taib; M K Thong; C H Yip; S H Teo
Journal:  Breast Cancer Res       Date:  2008-07-16       Impact factor: 6.466

7.  BRCA1 and BRCA2 missense variants of high and low clinical significance influence lymphoblastoid cell line post-irradiation gene expression.

Authors:  Nic Waddell; Anette Ten Haaf; Anna Marsh; Julie Johnson; Logan C Walker; Milena Gongora; Melissa Brown; Piyush Grover; Mark Girolami; Sean Grimmond; Georgia Chenevix-Trench; Amanda B Spurdle
Journal:  PLoS Genet       Date:  2008-05-23       Impact factor: 5.917

8.  Evaluation of unclassified variants in the breast cancer susceptibility genes BRCA1 and BRCA2 using five methods: results from a population-based study of young breast cancer patients.

Authors:  Eunjung Lee; Roberta McKean-Cowdin; Huiyan Ma; Zhengjia Chen; David Van Den Berg; Brian E Henderson; Leslie Bernstein; Giske Ursin
Journal:  Breast Cancer Res       Date:  2008-02-19       Impact factor: 6.466

9.  The Clinical Significance of Unknown Sequence Variants in BRCA Genes.

Authors:  Valentina Calò; Loredana Bruno; Laura La Paglia; Marco Perez; Naomi Margarese; Francesca Di Gaudio; Antonio Russo
Journal:  Cancers (Basel)       Date:  2010-09-10       Impact factor: 6.639

10.  Performance of in silico prediction tools for the classification of rare BRCA1/2 missense variants in clinical diagnostics.

Authors:  Corinna Ernst; Eric Hahnen; Christoph Engel; Michael Nothnagel; Jonas Weber; Rita K Schmutzler; Jan Hauke
Journal:  BMC Med Genomics       Date:  2018-03-27       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.